The growth of the global cervical cancer diagnostic market is driven by factors such as an increase in awareness regarding cervical cancer, the rise in consciousness of early diagnosis of cervical cancer, and the increasing number of diagnosis tests.
PORTLAND, Ore., April 28, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Cervical cancer diagnostic Market by Type (Pap Smear Tests, HPV test, Biopsy and ECC, Colposcopy Tests and Others), by Age group (20 to 40 years, above 40 years): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global cervical cancer diagnostic industry generated $7.8 billion in 2022 and is anticipated to generate $12.7 billion by 2032, witnessing a CAGR of 5.0% from 2023 to 2032.
Download Sample Report:https://www.alliedmarketresearch.com/request-sample/399
Prime determinants of growth
The growth of the global cervical cancer diagnostic market is driven by factors such as an increase in awareness regarding cervical cancer, the rise in consciousness of early diagnosis of cervical cancer, and the increasing number of diagnosis tests. However, the lack of awareness about diagnostic tests restricts the market growth. Moreover, a rise in government initiatives to increase the diagnosis of cervical cancer and developing economies presents new opportunities in the coming years.
Report coverage & details:
Report Coverage | Details |
Forecast Period | 2023-2032 |
Base Year | 2022 |
Market Size in 2021 | $7.8 billion |
Market Size in 2031 | $12.7 billion |
CAGR | 5.0 % |
No. of Pages in Report | 228 |
Segments Covered | Type, Age Group, and Region. |
Drivers | An increase in awareness regarding the cervical cancer diagnosis The rise in the number of research and development activities. |
Opportunities | A rise in government initiatives to promote cervical cancer diagnosis. |
Restraints | Lack of awareness about cervical cancer diagnostic tests |
Covid-19 Scenario
- The outbreak of the Covid-19 pandemic had a negative impact on the global cervical cancer diagnostic market, owing to the temporary decline in the diagnosis of cervical cancer during the lockdown.
- Restricting women's access to essential invasive and non-invasive investigations for cervical cancer diagnosis was hampered due to the closure of gynecology centers across the world, especially in the initial period of the pandemic.
The pap smear tests segment to maintain its leadership status throughout the forecast period
Based on type, the pap smear tests segment held the highest market share in 2022, accounting for nearly one-third of the global cervical cancer diagnostic market and is estimated to maintain its leadership status throughout the forecast period. The rise in awareness about cervical cancer is a major factor that propels the growth of pap smear tests across the globe. In addition, an increase in the number of diagnostic tests drives the growth of the market. However, the HPV tests segment is projected to manifest the highest CAGR of 5.9% from 2023 to 2032. HPV tests are notably done in the U.S., Canada, and Western European countries. Emerging countries such as Brazil, Russia, India, and China offer promising opportunities for the HPV tests market.
Procure Complete Report (228 Pages PDF with Insights, Charts, Tables, and Figures) @
https://www.alliedmarketresearch.com/checkout-final/cervical-cancer-diagnostic-market
The20 to 40years segment to maintain its leadership status throughout the forecast period.
Based on age group, the 20 to 40 years segment held the highest market share in 2022, accounting for nearly three-fourths of the global cervical cancer diagnostic market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to the prevalence of the cervical cancer among population of age group 20-40 along with the surge in number of patients visiting the hospitals for diagnosis of the cervical cancer. However, the above 40 years segment is projected to manifest the highest CAGR of 5.3% from 2023 to 2032, owing to the rise in diagnosis rate, and rising affordability.
North America to maintain its dominance by 2032
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for around two-fifths of the global cervical cancer diagnostic market revenue, and is likely to dominate the market during the forecast period. The government initiatives to promote diagnosis of cervical cancer contributes to the growth of the cervical cancer diagnostic market in North America. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.3% from 2023 to 2032. The rise in the awareness about early diagnosis of cervical cancer, owing to the presence of high-potential markets such as India and China, is expected to drive the growth of the cervical cancer diagnostic market.
Leading Market Players: -
- Abbott Laboratories
- Qaigen NV
- Carl Zeiss AG
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- Hologic Inc.
- F. Hoffmann-La Roche AG
- Siemens Healthineers
- CooperSurgical Inc.
- Dysis Medical ltd.
The report provides a detailed analysis of these key players in the global cervical cancer diagnostic market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry (Book Now with 10% Discount):
Oncology-Cancer Drugs Market By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2021-2030
Skin Cancer Treatment Market by Type (Melanoma, Non-Melanoma), by Therapy (Immunotherapy, Targeted Therapy, Chemotherapy), by Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Point of Care Diagnostics Market by Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Drugs Abuse Testing Kits, Others), by Mode Of Prescription (Prescription Based Devices, Otc Based Devices), by End User (Professional Diagnostic Centers, Research Laboratories, Home Care, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), by End User (Hospitals, Diagnostic centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020-2030
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Logo: https://mma.prnewswire.com/media/636519/3950895/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cervical-cancer-diagnostic-market-to-reach-12-7-billion-globally-by-2031-at-5-0-cagr-allied-market-research-301810638.html
